The following stories appear in full on today's Vidyya Medical News Service Web site.
November is National Alzheimer's Disease Month. In conjunction with the month, this Vidyya contains news and patient information regarding the disease. We also have information about some of the latest research being discussed at the 73rd Annual Meeting of the American Heart Association.
The number of Americans expected to develop Alzheimer's disease will increase by more than 250 percent by the year 2050. Currently, more than 4 million Americans suffer from the disease and that number is expected to grow to more than 14 million in 50 years due to the aging population in the United States.
In Alzheimer research news, Prana Biotechnology Limited has announced that a potential treatment for Alzheimer's Disease was presented at the annual meeting of the Society for Neuroscience in New Orleans. The drug, Clioquinol was approved for human use decades ago.
This Vidyya also contains an informational handout on Alzheimer's disease (AD). The handout explains that AD is a progressive, neurodegenerative disease characterized by memory loss, language deterioration, impaired visuospatial skills, poor judgment, indifferent attitude, but preserved motor function. AD usually begins after age 65, however, its onset may occur as early as age 40, appearing first as memory decline and, over several years, destroying cognition, personality, and ability to function. The handout also lists resources where families can elicit help.
In news from the American Heart Association Meeting, people with type 2 diabetes who take the weight-reducing medication Xenical(R) (orlistat) may significantly reduce their long-term risk of coronary heart disease and patients receiving Tracleertm (bosentan), the first oral therapy for pulmonary hypertension (PHT), demonstrated significant improvements in their exercise ability and hemodynamics. Tracleer is the first oral agent investigated for the treatment of pulmonary hypertension. Read about both the Xenical and the Tracleer studies in today's issue.
As always, we hope you enjoy the issue.